AU1888599A - Pharmaceutical compositions comprising disulfiram - Google Patents

Pharmaceutical compositions comprising disulfiram

Info

Publication number
AU1888599A
AU1888599A AU18885/99A AU1888599A AU1888599A AU 1888599 A AU1888599 A AU 1888599A AU 18885/99 A AU18885/99 A AU 18885/99A AU 1888599 A AU1888599 A AU 1888599A AU 1888599 A AU1888599 A AU 1888599A
Authority
AU
Australia
Prior art keywords
disulfiram
pharmaceutical compositions
angiogenesis
useful
formation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU18885/99A
Other languages
English (en)
Inventor
Moshe Marikovsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Publication of AU1888599A publication Critical patent/AU1888599A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
AU18885/99A 1998-01-11 1999-01-11 Pharmaceutical compositions comprising disulfiram Abandoned AU1888599A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL122892 1998-01-11
IL12289298A IL122892A0 (en) 1998-01-11 1998-01-11 Pharmaceutical compositions comprising a thiocarbamate
PCT/IL1999/000017 WO1999034784A2 (en) 1998-01-11 1999-01-11 Pharmaceutical compositions comprising disulfiram for inhibiting angiogenesis

Publications (1)

Publication Number Publication Date
AU1888599A true AU1888599A (en) 1999-07-26

Family

ID=11071076

Family Applications (1)

Application Number Title Priority Date Filing Date
AU18885/99A Abandoned AU1888599A (en) 1998-01-11 1999-01-11 Pharmaceutical compositions comprising disulfiram

Country Status (9)

Country Link
US (1) US6288110B1 (enExample)
EP (1) EP1047416B1 (enExample)
JP (1) JP2002500180A (enExample)
AT (1) ATE401879T1 (enExample)
AU (1) AU1888599A (enExample)
DE (1) DE69939155D1 (enExample)
DK (1) DK1047416T3 (enExample)
IL (1) IL122892A0 (enExample)
WO (1) WO1999034784A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6589987B2 (en) 1998-09-08 2003-07-08 Charlotte-Mecklenburg Hospital Authority Method of treating cancer using tetraethyl thiuram disulfide
US6706759B1 (en) 1998-09-08 2004-03-16 Charlotte-Mecklenburg Hospital Authority Method of treating cancer using dithiocarbamate derivatives
US6548540B2 (en) * 1998-09-08 2003-04-15 Charlotte-Mecklenburg Hospital Authority Method of treating cancer using dithiocarbamate derivatives
US7816403B2 (en) * 1998-09-08 2010-10-19 University Of Utah Research Foundation Method of inhibiting ATF/CREB and cancer cell growth and pharmaceutical compositions for same
AU2002226650A1 (en) * 2001-01-18 2002-07-30 Arnold Hoffman Redox therapy for tumors
US20040157837A1 (en) * 2002-11-07 2004-08-12 Serbedzija George N. Combinations for the treatment of fungal infections
WO2007065167A1 (en) * 2005-12-02 2007-06-07 The Johns Hopkins University Use of high-dose oxazaphosphorine drugs for treating immune disorders
WO2008034074A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Cyclosphosphamide in combination with anti-idiotypic vaccines
WO2008034071A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Method of identifying patients suitable for high-dose cyclophosphamide treatment
WO2008034076A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Cyclophosphamide in combination with immune therapeutics
WO2008068746A2 (en) * 2006-12-04 2008-06-12 Yeda Research And Development Co. Ltd. Disulfiram doses and treatment regimen suitable for treatment of angiogenesis-dependent disorders
US9026372B2 (en) * 2007-11-21 2015-05-05 Accentia Biopharmaceuticals, Inc. Methods for providing a system of care for a high-dose oxazaphosphorine drug regimen
WO2009067699A2 (en) * 2007-11-21 2009-05-28 Accentia Biopharmaceuticals, Inc. Methods for providing a system of care for an oxazaphosphorine drug regimen
EP2632450A1 (en) * 2010-08-31 2013-09-04 Avidal Vascular GmbH Compositions comprising a taxane for coating medical devices
JP6206939B2 (ja) * 2011-10-11 2017-10-04 国立大学法人 千葉大学 肝がん幹細胞阻害剤
WO2014152207A1 (en) 2013-03-15 2014-09-25 Mylan Laboratories, Inc. Hot melt granulation formulations of poorly water-soluble active agents
WO2015120254A1 (en) * 2014-02-06 2015-08-13 Texas Tech University System Disulfiram compositions and treatments for brain tumors
GB201407806D0 (en) 2014-05-02 2014-06-18 Ucl Business Plc Treatment of fibrosis
GB201519643D0 (en) * 2015-11-06 2015-12-23 Univ Wolverhampton Disulfiram formulation
WO2017177947A1 (zh) 2016-04-13 2017-10-19 诺马（北京）科技有限公司 局部注射双硫仑制剂治疗胸腹膜癌症的方法
EP3311843A1 (en) 2016-10-13 2018-04-25 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Compositions comprising dithiocarbamate and cyclodextrin
US11298396B2 (en) 2017-03-17 2022-04-12 Osaka University Agent for inhibiting or reducing light sensitivity
EP3813805A4 (en) * 2018-06-27 2021-08-25 Children's Medical Center Corporation INFLAMMATION INHIBITION COMPOUNDS
US11311538B2 (en) 2018-07-13 2022-04-26 Yale University Compositions and methods for targeting cancers
EP3693740A1 (en) 2019-02-07 2020-08-12 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Improved dithiocarmabate based compounds, therapies and diagnostics
KR20210049403A (ko) * 2019-10-25 2021-05-06 연세대학교 산학협력단 암의 예방 또는 치료용 조성물
EP4135660A1 (en) * 2020-04-16 2023-02-22 Atossa Therapeutics, Inc. Compositions and methods to reduce the infectivity of a virus
WO2021231814A1 (en) * 2020-05-14 2021-11-18 The Trustees Of Columbia University In The City Of New York Compositions and methods for the treatment and prevention of vascular malformations
US12070468B2 (en) * 2020-05-14 2024-08-27 The Trustees Of Columbia University In The City Of New York Compositions and methods for the treatment and prevention of vascular malformations
WO2022061171A1 (en) * 2020-09-18 2022-03-24 Spring Discovery, Inc. Combination therapies with disulfiram
US11065214B1 (en) * 2020-09-18 2021-07-20 Spring Discovery, Inc. Combination therapies with disulfiram
CN114376997B (zh) * 2021-10-10 2023-04-28 深圳市人民医院 一种新型IRE1a抑制剂紫草素及与双硫仑协同抗肿瘤组合方式

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0284879A3 (en) * 1987-03-17 1990-10-17 Merrell Dow Pharmaceuticals Inc. Method of inhibiting interleukin-1 release
US4870101A (en) * 1987-03-17 1989-09-26 Merrell Dow Pharmaceuticals Inc. Method of inhibiting interleukin-1 release
US5807884A (en) 1992-10-30 1998-09-15 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases

Also Published As

Publication number Publication date
WO1999034784A2 (en) 1999-07-15
IL122892A0 (en) 1998-08-16
WO1999034784A3 (en) 2000-09-08
EP1047416B1 (en) 2008-07-23
DE69939155D1 (de) 2008-09-04
EP1047416A2 (en) 2000-11-02
ATE401879T1 (de) 2008-08-15
JP2002500180A (ja) 2002-01-08
DK1047416T3 (da) 2008-11-17
US6288110B1 (en) 2001-09-11

Similar Documents

Publication Publication Date Title
WO1999034784A3 (en) Pharmaceutical compositions comprising disulfiram for inhibiting angiogenesis
CA2222676A1 (en) New pharmaceutical composition with anaesthetic effect
HUP0102899A3 (en) Process for preparation of compositions for the application of anti-inflammatory, especially antiseptic agents and/or agents promoting the healing of wounds, to the lower respiratory tract
GB9807639D0 (en) Anti-inflammatory agents
DE69500135D1 (de) Kosmetisches und/oder dermatologisches Mittel enthaltend Thermal- oder Mineralwasser und einen gegen Akne oder Älterung aktiven Agentsien
SE9603669D0 (sv) New combination
IL135951A0 (en) Antimutagenic compositions for the treatment and prevention of photodamage to skin
IT8567279A1 (it) Apparecchio per l'applicazione controllata, sul tessuto umano, di sostanze riducenti per realizzare microabrasioni.
AU2001286562A1 (en) Use of agaricus blazei murill to prevent or treat skin and other disorders
IL110943A (en) Compositions comprising an inhibitor of cholesterol synthesis for the treatment of skin disorders
NZ513096A (en) Compositions for treating inflammatory response
IT1264530B (it) Impiego dei polisaccaridi nelle neuropatie atrofico degenerative
PL330865A1 (en) Agents containing lectins and their application
MX9703693A (es) Tratamiento profilactico de dermatitis alergica por contacto.
PL329027A1 (en) Derivatives of benzopyrane exhibiting antagonistic activity in respect to leucotriene
JPS6434909A (en) Cosmetic
CA2156481A1 (en) 5-ht2 receptor antagonist compositions useful in treating venous conditions
NZ326345A (en) Composition containing diosgenin
EP0147185A3 (en) Therapeutic use of cytidyl disphosphocholine to increase neuronal acetylcholine
AU3971600A (en) Use of osanetant in the production of medicaments used to treat mood disorders
HRP970171A2 (en) Use of bradykinin antagonists for the preparation of medicaments to treat chronic fibrogenetic liver disease and acute liver disease
AUPP379698A0 (en) Using ngali nut oil to treat/relieve the pain of arthritis and other similar conditions
PL355292A1 (en) Combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino(2,3)-e indol-8-one and neuroleptics
AU3992897A (en) Use of sulbutiamine to obtain pharmaceutical compositions useful in the treatment of certain psychomotor and psycho-intellectual disorders
WO2000032155A3 (en) Skin care compositions containing zinc salts and retinoids

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase